Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

  • End date
    Oct 29, 2022
  • participants needed
  • sponsor
    RenJi Hospital
Updated on 29 January 2021


This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.

Condition Targeted Molecular Therapy, Adenocarcinoma, Malignant Adenoma, Adenocarcinoma, Chemotherapy, Chemotherapy, HEPATIC NEOPLASM, Liver Cancer, HEPATOCELLULAR CARCINOMA, Liver Cancer, Malignant Adenoma, liver cell carcinoma
Treatment Lenvatinib and Gefitinib
Clinical Study IdentifierNCT04642547
SponsorRenJi Hospital
Last Modified on29 January 2021


Yes No Not Sure

Inclusion Criteria

(1) Unlimited gender, aged 18-75 years; (2) Meets American Association for the
Study of Liver Diseases (AASLD) or European Association for the Study of the
Liver (EASL) clinical diagnostic criteria of hepatocellular carcinoma; (3)
Barcelona Clinic Liver Cancer (BCLC) Stage B or C, and there is at least one
measurable tumor in the liver (long diameter 1cm);(4) progressing after
standard treatment; (5) Unresponsive or resistant to Lenvatinib; (6) Child-
Pugh A or scored 7 B; (7) Eastern Cooperative Oncology Group performance
status score <= 1; (8) Platelet count >= 60x10^9/L, Prothrombin time prolonged
<= 6 seconds

Exclusion Criteria

(1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients
need long-term anticoagulant or anti platelet therapy and cannot stop the
drugs; (3) Patients with unstable or active ulcer or gastrointestinal
bleeding; (4) Heart disease requiring treatment or not well controlled high
blood pressure; (5) Patients with interstitial pneumonia; (6) Hepatic
encephalopathy or refractory ascites requiring treatment; (7) There is a clear
active infection; (8) Receiving radiotherapy/chemotherapy/interventional
therapy for tumor within 4 weeks before the start of the study; (9) Severe
insufficiency of important organs, such as severe cardiopulmonary
insufficiency; (10) Other accompanying anti-tumor treatments; (11) The
investigator assessed that the patient was unable or unwilling to comply with
the protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note